Thermo Fisher Scientific Continues Expansion
Thermo Fisher Scientific (Massachusetts, USA) celebrated the opening of its new single-use technology manufacturing site in Ogden, Utah, USA, and announced a $97 million expansion to its bioanalytical laboratory operations across three new locations in Virginia’s Greater Richmond region. The state‑of-the-art facility in Utah creates additional capacity for the development of new vaccines and therapies.
The Ogden site is a 55,000-square-ft facility that will manufacture customizable bioprocess container (BPC) systems. These BPCs are used for the delivery, processing, separation, storage, and transportation of critical liquids used in the production of biologics, vaccines, and cell and gene therapies. The site has hired more than 300 employees and has the potential to employ up to 450 people, adding to the 2000 strong workforce the company has across the state of Utah and establishing a critical hub for bioprocessing.
“The Ogden facility further strengthens our global manufacturing network, which has been growing to meet increasing demand for single-use consumables and critical raw materials,” said Mitch Kennedy, President, Single-Use Technologies, Thermo Fisher Scientific. “This new facility expands our presence in Utah and locating here gives us the ability to work closely with our Logan site, providing access to a talented workforce that is ideal for manufacturing.”
In Virginia, the existing laboratory services operation there comprises more than 300,000-square-ft, making it one of the largest laboratories of its kind in the world; it employs more than 1200 professionals. Thermo Fisher acquired the laboratories with the purchase of PPD, Inc., in December 2021. The expansion is part of Thermo Fisher’s $650 million multi-year investment, announced last year, to help ensure flexible, scalable, and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19. Longer term, the company plans to continue to invest in and connect the capabilities across the combined company. The bulk of the expansion will occur in immunochemistry and chromatography functions, as well as subsequent enhancements in biomarker and vaccine sciences. Two new bioanalytical laboratories will be established in Virginia’s Henrico County, and a third will be established at the VA Bio+Tech Park in the city of Richmond.
“Worldwide, we continue to expand our lab capacity to provide customers with high-quality bioanalytical lab services to advance their clinical research programmes,” said David M. Johnston, Ph.D., Senior VP and President, Clinical Research, Thermo Fisher Scientific. “These services are vital for drug development, as approximately 70% of data generated in clinical trials comes from analytical laboratory testing. We’re pleased to extend our partnership with Virginia, Henrico County, and the city of Richmond to continue our efforts to help customers deliver life-changing therapies to patients in need.”
For more information, please visit: https://corporate.thermofisher.com
New Study Uses MSPE with GC–MS to Analyze PFCAs in Water
January 20th 2025Scientists from the China University of Sciences combined magnetic solid-phase extraction (MSPE) with gas chromatography–mass spectrometry (GC–MS) to analyze perfluoro carboxylic acids (PFCAs) in different water environments.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ion used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
A Guide To Finding the Ideal Syringe and Needle
January 20th 2025Hamilton has produced a series of reference guides to assist science professionals in finding the best-suited products and configurations for their applications. The Syringe and Needle Reference Guide provides detailed information on Hamilton Company’s full portfolio of syringes and needles. Everything from cleaning and preventative maintenance to individual part numbers are available for review. It also includes selection charts to help you choose between syringe terminations like cemented needles and luer tips.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Oasis or Sand Dune? Isolation of Psychedelic Compounds
January 20th 2025Magic mushrooms, once taboo, have recently experienced a renaissance. This new awakening is partially due to new findings that indicate the effects of psilocybin, and its dephosphorylated cousin psilocin may produce long lasting results for patients who might be struggling with anxiety, depression, alcohol and drug abuse, and post-traumatic stress disorder. Hamilton Company has developed a methodology for the isolation and identification of 5 common psychedelic compounds used in the potential treatment of disease. The PRP-1 HPLC column resin remains stable in the harsh alkaline conditions ideal for better separations.
